A comprehensive review published in The BMJ finds that most “add-on” treatments marketed to improve IVF success rates lack robust clinical evidence to support their use. Researchers analyzed 150 unique add-ons and determined that the vast majority offer no proven benefit in increasing live birth rates, despite often carrying significant out-of-pocket costs for patients.
What are IVF add-ons?
IVF add-ons are optional procedures or medications offered to patients alongside standard in vitro fertilization cycles. These services, which include techniques like assisted hatching, endometrial scratching, and the use of specialized embryo culture media, are often presented as ways to boost the chances of a successful pregnancy. According to the Human Fertilisation and Embryology Authority (HFEA), these treatments are frequently marketed directly to patients who are already navigating the emotional and financial stresses of infertility.
Why the lack of evidence matters
The core concern raised by researchers is the discrepancy between marketing claims and clinical outcomes. The peer-reviewed study in The BMJ evaluated a wide range of interventions and concluded that for most, there is no high-quality evidence that they improve live birth rates. This creates a situation where patients may spend thousands of dollars on procedures that provide no measurable medical advantage. By comparing current data against previous clinical standards, the authors emphasize that many of these practices remain “unproven” rather than explicitly harmful, yet they continue to be sold to vulnerable populations.
How clinics frame these services
There is a notable contrast in how different regulatory bodies and clinics approach these treatments. While some clinics suggest that add-ons provide a personalized approach to fertility, the New York Times reports that the lack of standardized regulation allows for widespread adoption of these techniques without rigorous peer-reviewed validation. This contrasts sharply with standard IVF protocols, which are governed by strict clinical guidelines and established success metrics. The study highlights that the proliferation of these add-ons often outpaces the scientific research required to confirm their safety and efficacy.
Key takeaways for patients
- Evidence Gap: The majority of IVF add-ons have not been proven to increase the likelihood of a live birth.
- Financial Impact: These treatments often require additional out-of-pocket payments that are not covered by standard insurance.
- Regulatory Oversight: Patients should consult the HFEA treatment add-ons traffic light system, which categorizes procedures based on the quality of evidence available.
- Consultation: Experts recommend discussing any proposed add-on with a reproductive endocrinologist to determine if there is a specific, evidence-based reason for its use in an individual case.
What happens next for fertility treatments?
The findings are likely to increase pressure on fertility clinics to provide greater transparency regarding the success rates of elective add-ons. As medical organizations continue to advocate for evidence-based medicine, patients can expect more scrutiny regarding how these services are marketed. Moving forward, the focus will likely shift toward standardizing care and ensuring that patients have access to clear, data-driven information before deciding on additional procedures.
Worth a look